Literature DB >> 10967305

Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow.

P J Goadsby1, J D Classey.   

Abstract

Stimulation of the superior sagittal sinus in humans is pain-producing and in experimental animals leads to excitation of neurons in the caudal trigeminal nucleus and dorsal horns of the C(1/)C(2) cervical spinal cord: the trigeminocervical complex. Neuronal excitation is generally associated with an increase in local blood flow due to flow/metabolism coupling and we have used local blood flow in the trigeminocervical complex to examine the role of N-methyl-D-aspartate (NMDA)-mediated transmission in these neurons. Cats were anaesthetised with alpha-chloralose (60 mg/kg, ip; supplements 20 mg/kg iv) after surgical preparation under halothane (0.5-3%). Animals were paralysed with gallamine triethiodide to prevent possible movement artefact distorting the laser Doppler signals. The superior sagittal sinus was isolated for electrical stimulation (150 V; 250 microsec duration; 0.5, 1, 2, 5, 10 and 20 Hz) and the dorsal surface of the spinal cord exposed at the C(2) level. Blood flow was recorded from the region over the trigeminocervical complex by careful placement of a laser Doppler flow probe. Flow was recorded continuously by an online collection programme and NMDA-mediated transmission modulated by intravenous administration of MK-801 (0.4, 1 and 4 mg/kg, iv) at the stimulation frequency of 5 Hz. Stimulation of the superior sagittal sinus produced a stimulus-locked, frequency-dependent increase in blood flow in the region of the trigeminocervical complex. The mean maximum response was 39+/-4% at 20 Hz. MK-801 had no effect on the resting flow signal but markedly attenuated the SSS-evoked response in a dose-dependent manner. The mean maximum response after 4 mg/kg MK-801 was 13+/-2%. NMDA-mediated transmission is likely to be involved in nociceptive trigeminovascular transmission within the trigeminocervical complex and offers a possible target for both acute and preventative treatment of migraine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10967305     DOI: 10.1016/s0006-8993(00)02630-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

1.  GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex.

Authors:  R J Storer; S Akerman; P J Goadsby
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

2.  Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model.

Authors:  E Knyihár-Csillik; J Toldi; A Mihály; B Krisztin-Péva; Z Chadaide; H Németh; R Fenyo; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

3.  Effects of ionotropic glutamate receptor antagonists on rat dural artery diameter in an intravital microscopy model.

Authors:  K Y Chan; S Gupta; R de Vries; A H J Danser; C M Villalón; E Muñoz-Islas; A Maassenvandenbrink
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 4.  Modelling headache and migraine and its pharmacological manipulation.

Authors:  S E Erdener; T Dalkara
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 5.  Kynurenines and headache.

Authors:  Arpád Párdutz; Annamária Fejes; Zsuzsanna Bohár; Lilla Tar; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-06-04       Impact factor: 3.575

Review 6.  Migraine is a neuronal disease.

Authors:  J Tajti; A Párdutz; E Vámos; B Tuka; A Kuris; Zs Bohár; A Fejes; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2010-12-15       Impact factor: 3.575

Review 7.  Pathophysiology of Migraine: A Disorder of Sensory Processing.

Authors:  Peter J Goadsby; Philip R Holland; Margarida Martins-Oliveira; Jan Hoffmann; Christoph Schankin; Simon Akerman
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

Review 8.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

Review 9.  Glutamate receptor antagonists in the management of migraine.

Authors:  Kayi Chan; Antoinette MaassenVanDenBrink
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

10.  Characterization of opioid receptors that modulate nociceptive neurotransmission in the trigeminocervical complex.

Authors:  R J Storer; S Akerman; P J Goadsby
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.